Einloggen

Thematische Bibliographien / China. Lu jun. Lu jun, di 5

Inhaltsverzeichnis

Zeitschriftenartikel
Bücher

Auswahl der wissenschaftlichen Literatur zum Thema „China. Lu jun. Lu jun, di 5“

Autor: Grafiati

Veröffentlicht am 28. Juli 2024

Zuletzt aktualisiert am 31. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "China. Lu jun. Lu jun, di 5" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "China. Lu jun. Lu jun, di 5"

1

Wang, Mei-Hui. "Xiaolin: Un'esplorazione su barzellette e umorismo nella cultura cinese antica." Traduction et Langues 23, no. 2 (2024): 209–32. http://dx.doi.org/10.52919/translang.v23i2.1003.

Der volle Inhalt der Quelle

Annotation:

Xiaolin: An Exploration of Jokes and Humor in Ancient Chinese Culture This article is based on the study of the book "Xiaolin" (The Forest of Laughter) by Handan Chun 邯鄲淳 (ca.132-ca.221) of the Cao Wei 曹魏 period in the Eastern Han Dynasty 東漢 (25-220).The first book dedicated to jokes in ancient China. The realistic and satirical folk stories produced against the backdrop of the times, reflected the interest in life, humor and the educational sense of the literati, lower-class and common peopleof that period (Wang, 1981; Huang, 1999). Focusing on the only 29 jokes left in the book, the extracts

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Zhang, Xianyu, Shiyao Lu, Hui Li, et al. "Abstract P1-05-27: Liquid Biopsy for HER2 Status Assessment in Breast Cancer Using Surrogate DNA Methylation Markers." Cancer Research 83, no. 5_Supplement (2023): P1–05–27—P1–05–27. http://dx.doi.org/10.1158/1538-7445.sabcs22-p1-05-27.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: Emerging HER2-targeted drugs especially antibody–drug conjugates (ADCs) are promising and provide more options for breast cancer management. Current assessment of HER2 status and treatment decisions are mainly dependent on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on the primary tumor tissues. With the disease progression, the molecular status of the tumor may evolve and become discordant with the primary site. However, longitudinal monitoring of HER2 status is limited by infeasible repeated sampling of the tumor tissues. A non-invasive and a

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Cai, Xiaobo, Min Cao, Huihui Guo, et al. "Abstract 1883: A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors." Cancer Research 84, no. 6_Supplement (2024): 1883. http://dx.doi.org/10.1158/1538-7445.am2024-1883.

Der volle Inhalt der Quelle

Annotation:

Abstract Pancreatic cancer is a malignant tumor with high incidence and mortality. It is difficult to diagnose and detect in the early stage, with low surgical resection rate and high recurrence and metastasis rate after surgery. At present, the clinical therapeutic strategy is extremely limited. The first-line Standard of Care (SOC) for unresectable pancreatic cancer is chemotherapy. The preferred regimen includes gemcitabine combined with albumin paclitaxel or FOLFIRINOX (5-FU+Oxaliplatin+Irinotecan). Due to the limited long-term benefits and toxic side effects of chemotherapy, targeted ther

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Chen, Naifei, Chengfei Pu, Lingling Zhao, et al. "Abstract 1130: A phase 1 dose escalation study of GCC19CART - a novel CoupledCAR therapy for subjects with metastatic colorectal cancer." Cancer Research 83, no. 7_Supplement (2023): 1130. http://dx.doi.org/10.1158/1538-7445.am2023-1130.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in hematologic malignancies but limited success in solid tumors. GCC19CART, the first clinical candidate from the CoupledCAR solid tumor platform, is designed to overcome the limitations of conventional CAR T-cells in solid tumor malignancies by pairing solid tumor CAR T-cells with CD19 targeting CAR T-cells to amplify proliferation and activation of the solid tumor CAR T component. GCC19CART targets guanylate cyclase-C (GCC) which is expressed in the metastatic lesions of 70%-80% of subj

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Mao, Lili, Jun Guo, Lingjun Zhu, et al. "Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study." Cancer Research 82, no. 12_Supplement (2022): CT519. http://dx.doi.org/10.1158/1538-7445.am2022-ct519.

Der volle Inhalt der Quelle

Annotation:

Abstract Purpose: No targeted therapy has been approved for NRAS-mutant melanoma. We evaluated the safety and tolerability and determined the recommended phase 2 dose (RP2D) of FCN-159, a selective MEK1/2 inhibitor, in patients with NRAS-mutant advanced melanoma. Methods: This single-arm, open-label, dose-escalation, phase 1A study in China (NCT03932253) enrolled patients with unresectable stage III/IV melanoma harboring NRAS mutations. Patients received FCN-159 in doses escalating from 0.2 mg until the maximum tolerated dose (MTD). Oral FCN-159 was given once in the single-dose period and onc

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Ji, Yinghua, Honglan Qu, Feidu Zhou, et al. "Abstract PO2-16-08: Adjuvant Treatment Selection for County-Level Patients with HR+/HER2- Early Breast Cancer in a Real-Life Setting in China." Cancer Research 84, no. 9_Supplement (2024): PO2–16–08—PO2–16–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-16-08.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: CHASE001 (NCT05544123), a prospective, non-interventional multicenter study exploring real-world treatment and referral behavior of Chinese county patients (pts) with HER2+ or HR+/HER2– breast cancer is ongoing since September 2022. A prespecified interim analysis (IA) on 750 HER2+ and HR+/HER2- early breast cancer (eBC) was reported at the ESMO Congress 2023. In the 2nd IA from CHASE001, adjuvant treatment selection for patients with HR+/HER2- eBC will be evaluated. Methods: The study was designed to enroll 2500 pts, including four cohorts (HER2+ eBC, HR+/HER2-eBC, HER2+

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Abass, Athraa A., Radhwan Alhashem, and Ghazwan Alhashem. "A cross-sectional study on the symptoms of depression in dental students in Kerbela." Technium BioChemMed 11 (November 29, 2024): 16–22. http://dx.doi.org/10.47577/biochemmed.v11i.12117.

Der volle Inhalt der Quelle

Annotation:

Doktorchik C, Patten S, Eastwood C, et al. Validation of a case definition for depression in administrative data against primary chart data as a reference standard. BMC Psychiatry. 2019;19(1):9. doi:10.1186/s12888-018-1990-6 Mancuso E, Sampogna G, Boiano A, Della Rocca B, Di Vincenzo M, Lapadula MV, Martinelli F, Lucci F, Luciano M. Biological correlates of treatment resistant depression: a review of peripheral biomarkers. Front Psychiatry. 2023 Oct 24; 14:1291176. doi: 10.3389/fpsyt.2023.1291176. PMID: 37941970; PMCID: PMC10628469. Machado MO, Veronese N, Sanches M, et al. The association of

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Frentzas, Sophia, Haesong Park, George Budd, et al. "Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients." Cancer Research 84, no. 9_Supplement (2024): PO1–04–01—PO1–04–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-04-01.

Der volle Inhalt der Quelle

Annotation:

Abstract Introduction: ARX788 is a next-generation anti-HER2 antibody-drug conjugate (ADC) conjugated to amberstatin269 (AS269), a potent cytotoxic tubulin inhibitor. ARX788 is highly stable with nearly identical PK profiles for the total ADC and the total antibody due to proprietary site-specific oxime conjugation chemistry. The stability of ARX788 results in limited systemic toxicity and increased targeted delivery of payload to tumor cells. Clinical benefit of ARX788 has been observed in patients (pts) with HER2-positive (HER2-pos) breast cancer (BC) in multiple clinical trials and recently

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Liu, Hong, Li Ma, Xu Wang, et al. "Abstract P1-12-11: Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer." Cancer Research 83, no. 5_Supplement (2023): P1–12–11—P1–12–11. http://dx.doi.org/10.1158/1538-7445.sabcs22-p1-12-11.

Der volle Inhalt der Quelle

Annotation:

Abstract Objective: Pyrotinib, an oral irreversible pan-HER receptor tyrosine kinase inhibitor, showed promising efficacy and manageable safety profiles in the treatment of HER-2 positive breast cancer. Diarrhea is the most common adverse event associated with pyrotinib. This study aimed to evaluate the incidence and management of diarrhea secondary to pyrotinib in Chinese patients with HER-2 positive breast cancer. Methods: In this prospective real-world study, consecutive patients aged over 18 with HER-2 positive breast cancer and an Eastern Cooperative Oncology Group performance status (ECO

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Amin, Adam Aliathun, and Eva Imania Eliasa. "Parenting Skills as The Closest Teacher to Early Childhood at Home." JPUD - Jurnal Pendidikan Usia Dini 17, no. 2 (2023): 312–30. http://dx.doi.org/10.21009/jpud.172.09.

Der volle Inhalt der Quelle

Annotation:

Parents play an important role in the development of their children. This research reflects the role of parents in developing children. Through four stages of identification, screening, eligibility, and acceptable results, this method uses a systematic literature review using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) method. The findings from the fourteen articles examined show that parenting skills play an important role in a child's growth and development from birth to death. The determining factor in the development of physical, motoric, moral, language

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "China. Lu jun. Lu jun, di 5"

1

E Yu bian qu ge ming shi bian ji bu., ed. Xin si jun di wu shi kang zhan li cheng. Hubei ren min chu ban she, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Bing, Meng, and Wang Yuanping, eds. Ba lu jun. Zhong yang wen xian chu ban she, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Baoxun, Dong, ed. Ba lu jun shi: Balujunshi. Qingdao chu ban she, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

di 50. Jun shi bian xie zu China. Lu jun. Zhongguo ren min jie fang jun lu jun di wu shi jun jun shi, 1949-1985. s.n.], 1987.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Shaojun, Wang, ed. Ba lu jun zong bu. Jie fang jun chu ban she, 2005.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Yang, Maolin. Ba lu jun zai Shanxi. San Jin chu ban she, 2020.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

China (Republic : 1949- ). Guo fang bu. Jun wu ju. Shi zheng chu., ed. Guo min ge ming jun lu jun di shi ba jun jun shi. Guo fang bu jun wu ju shi zheng chu, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Zhang, Junfeng. Wo shi ba lu jun. Hunan ren min chu ban she, 2017.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

"Zhongguo kang Ri zhan zheng jun shi shi liao cong shu" bian shen wei yuan hui. Ba lu jun, tu pian. Jie fang jun chu ban she, 2016.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Zhang, Zhelong. Kang Ri de di ba lu jun. Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!